Adcentrx Therapeutics to Present Preclinical Data for Nectin-4 ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024

Posted on by

Preclinical data support clear differentiation of Adcentrx’s platform and lead program, ADRX-0706, currently being evaluated in a Phase 1a/b clinical trial SAN DIEGO, April 1, 2024 /PRNewswire/ — Adcentrx Therapeutics (“Adcentrx”), a biotechnology company revolutionizing Antibody-Drug…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.